摘要
目的:观察紫杉醇联合表阿霉素(TE方案)与诺维本联合表阿霉素(NE方案)治疗晚期乳腺癌的疗效和不良反应。方法:70例晚期乳腺癌患者随机分为TE组34例和NE组36例。结果:TE组总有效率(64.7%)和复治有效率(60.0%)高于NE组(38.9%和28.6%),中位疾病进展时间长于NE组(两组分别为9.6个月和7.2个月),(P<0.05);两组初治有效率和中位生存期无显著差异(P>0.05)。不良反应以骨髓抑制、胃肠反应和脱发为主,大多为Ⅰ～Ⅱ度,两组间无显著差异(P>0.05);NE组静脉炎发生率高于TE组,TE组关节肌肉酸痛发生率相对较高,但均可耐受。结论:紫杉醇联合表阿霉素和诺维本联合表阿霉素对晚期乳腺癌均有较好的疗效和耐受性,但TE组对复治患者疗效更好,可作为复治的晚期乳腺癌患者首选方案。
Objective: To evaluate the efficacy and toxicity of paclitaxel and epirubicin (TE regimen) versus navelbine and epirubicin (NE regimen) in the treatment of advanced breast cancer. Methods: A total of 70 patients with advanced breast cancer proved pathologically were randomly divided into TE group (n=34) and NE group (n=36). Results: TE regimen produced a higher response rate (RR) than NE regimen in the whole cases(64.7% and 38.9%, respectively) and the retreatment cases (60.0% and 28.6%, respectively) (P<0.05). The median time to progress (TTP) in TE group was longer than that in NE group(9.6 months and 7.2 months, respectively) (P<0.05). However, there was no significant difference between two groups in the RR of the initial treatment and the median survival (P>0.05). The main toxicities were bone marrow depression?digestive reaction and alopecia (mainly grade Ⅰ~Ⅱ), which were similar in two groups. Phlebitis was more common in NE group than in TE group, but articular and muscular soreness was more serious in TE group. All side effects were toleable. Conclusions: Both of the two regimens are effective and well-tolerated in the treatment of advanced breast cancer. However, TE regimen is more effective in retreatment cases, and could be considered as a relevant regimen for retreated patients.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2004年第18期24-25,28,共3页
Chinese Journal of Clinical Oncology
关键词
紫杉醇
诺维本
表阿霉素
联合化疗
乳腺肿瘤
Paclitaxel Navelbine Epirubicin Combined chemotherapy Breast neoplasma
